George Jones will be the new Chief Commercial Officer (CCO) of Biofrontera Inc., effective August 25, 2025.
In this role, Mr. Jones will oversee the Company’s commercial functions, including sales, marketing, and market access. He will report directly to CEO Hermann Luebbert, PhD.
This move follows the recent announcement of an agreement to acquire all rights and assets related to Ameluz and RhodoLED for the U.S. market, including the U.S. Food and Drug Administration (FDA) approval and all patents, from its former parent company—Biofrontera AG.
As announced, the Company will now pay a monthly Ameluz royalty between 12% and 15%, as opposed to the previously effective transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. These changes will bring Biofrontera significantly closer to cash break-even.
Most recently, Mr. Jones served as Chief Operating Officer at UpScriptHealth. He was also Vice President Global Marketing and Commercial Operations at Currax Pharmaceuticals. Prior to Currax, at Pernix Therapeutics, Mr. Jones was promoted to Vice President of Sales and Marketing. Earlier in his career, he was the Senior Director of Market at Depomed, Inc.
“I am thrilled to join Biofrontera at such an exciting time in its evolution,” says Mr. Jones in a news release. “The company’s commitment to breakthrough dermatology treatments and its focus on patient outcomes align closely with my passion for bringing innovative therapies to market. I look forward to working with our commercial organization and cross-functional partners to deliver value for patients, physicians, and stockholders.”
